1.. Introduction {#S0001}
================

The prevalence of psychotic symptoms indicates a potential public health concern (Nuevo et al., [2012](#CIT0039)). It is estimated that around one in 150 people will receive a diagnosis for a psychotic disorder during their lifetime (Moreno-Kustner, Martin, & Pastor, [2018](#CIT0037)), and the total societal cost for psychosis is anticipated to rise to £6.5 billion by 2026 (Kings Fund, [2008](#CIT0029)). The cause of psychosis is currently unclear and probably multi-faceted. However, there is increasing evidence indicating that trauma experienced during childhood can play a pivotal role in the development and perpetuation of psychotic symptoms (Hardy, [2017](#CIT0017); Varese et al., [2012](#CIT0059)). The literature suggests that exposure to traumatic experiences such as, physical abuse, bullying, sexual abuse, and neglect may culminate in negative beliefs about the self, others and the world. These beliefs can lead to viewing the self as vulnerable, and the perception that ordinary events are threatening, resulting in psychotic symptoms such as, paranoia and distorted perceptions of regular stimuli (Kelleher et al., [2013](#CIT0027)). Eye Movement Desensitization and Reprocessing (EMDR) is an effective treatment for trauma (Shapiro, [1995](#CIT0047), [2018](#CIT0049)), which aims to desensitize discomfort caused by traumatic experiences and reprocess them within the individual's autobiographical memory which can achieve symptom relief (Hardy, [2017](#CIT0017); van der Vleugel, van den Berg, & Staring, [2012](#CIT0058)). Increasing evidence acknowledging the relationship between trauma and psychosis indicates that EMDR could be a vital addition to the treatment of psychosis (Sin & Spain, [2017](#CIT0050); Valiente-Gomez et al., [2017](#CIT0053)).

Antipsychotic medication is regarded as the cornerstone of treatment for psychosis (Jones et al., [2006](#CIT0025)). However, it is reported that around 50% of people being treated with antipsychotic medication continue to experience distressing psychotic symptoms (Pankey & Hayes, [2003](#CIT0040)); and non-adherence to antipsychotic medication owing to intolerable side effects and poor efficacy contributes significantly to relapse and readmission for people with a psychotic disorder (Haywood et al., [1995](#CIT0020)). Adding psychological therapies such as Cognitive Behavioural Therapy (CBT), alongside antipsychotic medication is now common practice, and their addition has demonstrated their potential as an effective treatment for psychosis (Hazell, Haywood, Cavanagh, & Strauss, [2016](#CIT0021); Lutgens, Gariepy, & Malla, [2017](#CIT0033)). Although CBT appears to be beneficial there is limited evidence regarding its clinical significance over treatment as usual for preventing relapse for people with psychosis (Jauhar et al., [2014](#CIT0024); Morrison et al., [2018](#CIT0038)). There is room for future research into the treatment of the trauma experiences for people with psychosis, such as EMDR, that could be used as an alternative, or adjunctive, to current treatments.

Recent systematic reviews evaluating a range of trauma-focussed therapies (TFTs) in people with psychosis provide preliminary support for the usefulness and safety of TFTs for the treatment of trauma-associated symptoms of psychosis, and promising effects for the positive symptoms of psychosis (Brand & McEnery, [2018](#CIT0004); Swan, Keen, Reynolds, & Onwumere, [2017](#CIT0051); Sin & Spain, [2017](#CIT0050); Valiente-Gomez et al., [2017](#CIT0053)). Current literature also suggests that adding TFTs to treatment for people with a psychotic disorder and co-morbid PTSD can generate better quality of life, and reduce costs from shorter hospital admissions than the current standard treatment for psychosis (de Bont et al., [2019](#CIT0009)). Therefore, the aim of this systematic review was to evaluate the safety, effectiveness, and acceptability of EMDR as a treatment for people with psychosis.

2.. Methods {#S0002}
===========

2.1.. Protocol and registration {#S0002-S2001}
-------------------------------

This review followed the Preferred Reporting Items for Systematic Reviews and Meta- Analysis (PRISMA) guidelines (Moher, Liberati, Tetzlaff, & Altman, [2009](#CIT0036)), and the protocol was registered with PROSPERO (CRD42018106756).

2.2.. Literature search {#S0002-S2002}
-----------------------

Four databases were searched from their year of inception to July 2018: Cochrane, EMBASE via OvidSP, MEDLINE via OvidSP, PsychINFO via OvidSP. Grey literature was searched using the Francine Shapiro Library (FSL), and other Grey literature sites (OpenGrey, [www.who.int/trialsearch](http://www.who.int/trialsearch) and [www.clinicaltrials.gov](http://www.clinicaltrials.gov)) were searched for any unpublished studies, dissertations, or theses to minimize publication bias (Higgins & Green, [2011](#CIT0022)). The FSL is a collection of scholarly articles, conference presentations, and other relevant writings relating to EMDR. The final search strategies were developed using key terms: (Eye Movement Desensiti\*ation and Reprocessing OR EMDR) AND (Psycho\* OR Schizo\* OR Delusion\* OR Hallucination\*). The full search strategy used for MEDLINE can be seen in the supplementary material (Table S1). The FSL does not allow for the use of truncation symbols or multi-term searching, and so all key terms were searched separately. This topic is in its infancy as individuals with psychotic disorders are almost always excluded from studies involving effective trauma treatments, due to fear of exacerbating their symptoms (Ronconi, Shiner, & Watts, [2014](#CIT0042)). Therefore, no date limits were applied in order to yield a sufficient number of results.

Reference lists of relevant retrieved papers were screened for additional studies, along with reference lists within the book 'EMDR Therapy for Schizophrenia and other Psychoses' by Miller ([2016](#CIT0035)). After the searches were complete a new follow-up paper from one of the included studies was published and included in the results (van den Berg et al., [2018](#CIT0054)).

2.3.. Inclusion criteria {#S0002-S2003}
------------------------

The final selection of papers was based on the following inclusion criteria: Participants of any age and diagnosed with a psychotic disorder; or mental health disorder where psychotic features were present and measured.Studies using a recognized EMDR protocol.Studies using EMDR alone, or in combination with treatment as usual (TAU).Studies reporting the effect of EMDR on psychotic symptoms.Studies written in English language at full text.Studies conducted using any research design including qualitative, quantitative, and mixed methods methodologies, with or without control groups.

The decision to include a wide range of designs including those often considered less rigorous was based on the need to provide a comprehensive representation of this novel area of emerging evidence.

2.4.. Quality assessment {#S0002-S2004}
------------------------

The quality of the studies did not influence the inclusion criteria, but the strengths and weaknesses of the individual studies were drawn upon to inform the discussion. Due to the variance in study designs, three different quality assessment tools to aid this process were required to suit the needs of all the studies included.

The Cochrane 'Risk of Bias assessment tool' was used to determine the methodological quality of the included clinical trials (Higgins & Green, [2011](#CIT0022)). Case series and case reports were assessed using The Joanna Briggs Institute (JBI) critical appraisal checklists for case series and case reports (Aromataris & Munn, [2017](#CIT0002)). An overall judgement of the methodological quality was made based on the questions from the checklists that are most important for the specific cases.

If information was not found in included papers it was sought from adjoining publications, or by contacting the primary authors. Judgements of quality were summarized in the results section.

2.5.. Data extraction {#S0002-S2005}
---------------------

Data was systematically extracted onto an Excel spreadsheet tailored to the review question. Data extracted included: authors, year of publication, country, study design, study setting, inclusion and exclusion criteria, sample size, method of randomization, description of the intervention, fidelity checks, control/comparator group, outcome measures, length of follow- up, results and any conclusions drawn. Attempts were made to contact primary authors to obtain any missing data. de Bont et al.'s ([2016](#CIT0008)) publication does not report all the necessary information relating to the trial design. Therefore, earlier publications reporting the same study (de Bont et al., [2013a](#CIT0007); van den Berg et al., [2015](#CIT0056)) were referred to for the relevant information. The extracted data was tabulated and examined for heterogeneity.

2.6.. Data analysis {#S0002-S2006}
-------------------

A Narrative Synthesis was performed following guidance from Petticrew and Roberts ([2008](#CIT0041)). The studies were described and organized into logical categories based on the study design. The findings were then analysed within the individual categories, and then synthesized across all categories.

3.. Results {#S0003}
===========

A total of 487 potentially relevant papers were yielded through searching the four databases (Cochrane, EMBASE, MEDLINE, PsychINFO), and the Francine Shapiro Library. No additional relevant papers were identified via reference list, or grey literature searching. After duplicates were removed, a total of 424 citation and abstracts were screened simultaneously for relevance. At this stage, 404 records were excluded leaving 20 papers to be screened at full-text for inclusion in the review. Fourteen papers were excluded with reasons detailed in [Figure 1](#F0001), leaving a total of six papers which met the inclusion criteria and were included in the review. 10.1080/20008198.2019.1711349-F0001Figure 1.Flowchart.

3.1.. Quality assessment {#S0003-S2001}
------------------------

### 3.1.1.. Quality of the included clinical trials {#S0003-S2001-S3001}

The overall quality of the three trials is limited (see [Table 1](#T0001)). de Bont et al.'s ([2016](#CIT0008)) Randomized controlled trial (RCT) is of the highest quality. de Bont et al.'s ([2016](#CIT0008)) publication does not report all information relating to the trial design, therefore, earlier publications reporting the same study were referred to for the quality assessment (de Bont et al., [2013a](#CIT0007); van den Berg et al., [2015](#CIT0056)).10.1080/20008198.2019.1711349-T0001Table 1.Risk of bias in the included clinical trials.Study Authors and dateRandom Sequence GenerationAllocation ConcealmentBlinding of participants and personnelBlinding of outcome assessmentIncomplete outcome dataSelective reportingAny other biasKim et al. ([2010](#CIT0028))Randomization method not reported.Not reportedNot reportedOutcome assessor was blind to the treatment condition.Attrition was reported and no significant differences in the rates of drop-outs between the groups in any of the assessment intervals were found.The study reports all expected outcomes.1)Self-reported outcome measure.\
2)The attending psychiatrist was responsible for the inclusion of participants.van den Berg and van der Gaag ([2012](#CIT0057))Open trial. No randomizationNot reportedNot reportedNot reportedReasons for attrition were reported and ITT analyses with LOCF (n-27) were undertaken.The study reports all expected outcomes. de Bont et al. ([2016](#CIT0008))Participants were randomized using the scientific randomization program on the Internet ([www.randomizer.org](http://www.randomizer.org)) by the independent randomization bureau of the Parnassia Psychiatric Institute.Participants were randomized to each of the three groups using the scientific randomization program on the Internet ([www.randomizer.org](http://www.randomizer.org)) by the independent randomization bureau of the Parnassia Psychiatric Institute.Not reportedOutcome assessors were blind to treatment condition.Attrition was reported. ITT analyses with the LOCF (n = 155) were undertaken. Missing data was replaced with a negative value.This study reports all expected outcomes.1)Self-reported outcome measure.[^1]

Only one trial reported a suitable method of randomization (de Bont et al., [2016](#CIT0008)), and one was an open trial and did not randomize at all (van den Berg & van der Gaag, [2012](#CIT0057)). Only de Bont et al. ([2016](#CIT0008)) reported a form of allocation concealment. All studies had small sample sizes with insufficient power for the statistical tests necessary to evaluate the effectiveness of EMDR.

### 3.1.2.. Quality of case series and case report {#S0003-S2001-S3002}

The overall quality of McGoldrick, Begum, and Brown's ([2008](#CIT0034)) case series and Laugharne, Marshall, Laugharne, and Hassard's ([2014](#CIT0032)) four vignettes was deemed adequate according to the JBI checklist (see Figure S1 in the supplementary material). However, neither reported complete inclusion of all people who were treated, and further selection bias occurred in both as they only reported cases that they believed had benefited from EMDR treatment. Kratzer, Heinz, and Schennach's ([2017](#CIT0031)) case report is of high quality according to the JBI checklist (see Figure S2 in the supplementary material).

3.2.. Overview of studies {#S0003-S2002}
-------------------------

The six included studies were published between 2008 and 2017 and evaluated EMDR for the psychological treatment of people with psychotic symptoms. Two studies were conducted in the UK (McGoldrick et al., [2008](#CIT0034); Laugharne, Marshall, Laugharne, & Hassard, [2014](#CIT0032)), two in the Netherlands (de Bont et al., [2016](#CIT0008); van den Berg & van der Gaag, [2012](#CIT0057)), and one in Germany (Kratzer et al., [2017](#CIT0031)) and south Korea (Kim et al., [2010](#CIT0028)). The study characteristics including the outcomes can be seen in [Table 2](#T0002).10.1080/20008198.2019.1711349-T0002Table 2.Summary of study characteristics and outcomes.Study authorsAimsStudy design and nPopulationInterventionControl/\
ComparatorOutcomeFollow-upKim et al. ([2010](#CIT0028))To test the feasibility and effectiveness of EMDR for inpatients with a psychotic disorder.RCT (Pilot study)\
(n = 45)Participants diagnosed with Schizophrenia and an inpatient statusStandard eight-phase EMDR protocol\
(n = 15)PMR (n = 15) and TAU (n = 15)**Treatment effect sizes for change in total PANSS scores between baseline and 3-months**:\
EMDR -- 0.82 PMR -- 0.66 TAU -- 0.63\
No adverse events.**% of people readmitted to hospital at 2-year follow-up**\
EMDR -- **18%**.\
PMR -- **42%**.\
TAU -- **33%.**van den Berg and van der Gaag ([2012](#CIT0057))To test the feasibility and effects of EMDR in patients with a psychotic disorder and a comorbid PTSD.Open pilot trial (n = 27)Participants diagnosed with Schizophrenia Spectrum Disorder and current PTSDStandard eight-phase EMDR protocol (Dutch translation)None**Wilcoxon Signed Rank Tests**\
**DRS** scores **(z = −2.02\*)**\
**AHRS** scores **(z = −2.17\*)**\
**PSYRATS** scores **(z = −2.67\*)**\
**GPTS**\
Baseline mean -- **73.04**.\
End of treatment mean -- **67.92**\
**There were no admissions in general or psychiatric hospital.**Nonede Bont et al. ([2016](#CIT0008))To examine secondary effects of TFTs of PTSD in patients with chronic psychotic disorders.RCT (n = 155)Participants with a Psychotic Disorder and PTSDStandard eight-phase EMDR protocol (Dutch translation)\
(n = 55)Waitlist (n = 47) and PE (n = 53)**GPTS mean scores and 95% CIs**\
**EMDR  PE  WL**\
Baseline**82.7  88.8  83.8**\
Post-treatment**68\*** (60.6--75.5) **67.3\*** (60.1--74.5) **82.7**(74.9--90.6)\
**AHRS mean scores and 95% CIs**\
**EMDR  PE  WL**\
Baseline**24.5  21.7  23.0**\
Post-treatment**16.8**(11.2--22.3) **18.8**(13.2--24.4) **24.2**(17.8--30.6)\
**% of people in remission from a psychotic disorder**\
Baseline:EMDR -- 45.5% PE -- 47.2% WL -- 40.4%.\
Post-treatment:EMDR -- 56.8%\* PE -- 59.6%\* WL -- 30.8%.\
There was no difference in dropout between the PE 13 participants \[24.5%\] and EMDR 11 participants \[20.0%\] (P = .57).\
The treatments were significantly associated with less adverse events.**GPTS**\
6-month follow-up\
**WL**-70.2 (62.7--77.7)\
**EMDR**-65.0 (57.7--72.3)\
**PE**-78.3\* (70.5--86.2)\
No change at 12-month follow up (van den Berg et al., [2018](#CIT0054))\
**AHRS**\
6-month follow-up\
**WL**-16.1(10.4--21.7)\
**EMDR**-22.5 (16.6--28.4)\
**PE**-16.8 (10.6--23.1)\
No change at 12-month follow up (van den Berg et al., [2018](#CIT0054))\
**Remission**\
6-month Follow-up\
**WL** -- 45%\
**EMDR** -- 55.8%\
**PE** -- 60%McGoldrick et al. ([2008](#CIT0034))To describe four consecutive cases of ORS treated successfully with EMDR.Case Series (n = 4)Participants diagnosed with a delusional disorder-somatic subtypeStandard eight-phase EMDR protocol (accept case 1 which used the EMDR protocol described in Shapiro's early papers (Shapiro, [1989a](#CIT0045), [1989b](#CIT0046))NoneCases were assessed according to DSM criteria before and after EMDR.\
**Post-treatment**:\
**Case 1** -- Complete resolution of all symptoms.\
**Case 2** -- Resolution of some symptoms.\
**Case 3** -- Complete resolution of all symptoms.\
**Case 4** -- Complete resolution of all symptom and marked improvement in social functioning.**Case 1** -- **6-month follow-up**:\
Symptom free. Discontinued all psychotropic medication.\
**10- year follow-up**:\
Symptom free and returned to work.\
**Case 2** -- **6-month follow-up**:\
Symptom free.\
**Case 3** -- **5-year follow-up**:\
Symptom free and discontinued antipsychotic medication.\
**Case 4** -- **5-year follow up**:\
Symptom free.Laugharne et al. ([2014](#CIT0032))To present four vignettes of people with a psychotic disorder receiving EMDR for symptoms of PTSDCase series (n = 4)Participants with an established Psychotic diagnosis who have received EMDR for the treatment of PTSDStandard eight-phase EMDR protocolNone**Post-treatment**:\
**Case 1 --** Fewer nightmares. Depression and anxiety much improved. General functioning improved,\
**Case 2 --** Marked reduction in distress associated with traumatic memories. Reduction in flash backs and nightmares.\
**Case 3 --** reduction in distress associated with images from nightmares.\
**Case -- 4** -- No longer has panic attack and reduced paranoia.**Case 1 -- 6-year follow- up**:\
Significant improvement in functioning and reduction in service use.\
**Case 2 -- 5-years follow-up**:\
Currently well and only one relapse during the 5 years.\
**Case 3 -- 2-year follow-up**:\
Nightmares significantly reduced. Agitation and persecutory thoughts diminished.\
**3 -- year follow-up**:\
Free from drug misuse. Overall functioning improved. Intrusive thoughts remain. One relapse when medication was stopped.\
**Case 4 -- 4-year follow-up**:\
Episodes of psychosis no longer included delusions targeted by EMDR. Some psychotic symptoms still remain. Discharged from mental health services.Kratzer et al. ([2017](#CIT0031))No clearly stated aim.Case report (n = 1)Participant diagnosed with Schizotypal Personality Disorder and PTSD reporting psychotic symptoms16 individual 50-min treatment sessions of CBT and ten additional 100-min sessions of EMDR.None**Post-treatment**:\
PANSS-22 score decreased from 64 to 46 which is clinically significant.\
Resolution of PTSD and positive psychotic symptoms.**6-month follow-up**:\
symptoms levels decreased eve further. Improved functioning. Reduction in service use.[^2]

### 3.2.1.. Study design {#S0003-S2002-S3001}

The included study designs comprised of an RCT (de Bont et al., [2016](#CIT0008)); two case series, both including four individual cases (McGoldrick et al., [2008](#CIT0034); Laugharne et al., [2014](#CIT0032)); one single case report (Kratzer et al., [2017](#CIT0031)) and two pilot studies, one used an RCT design (Kim et al., [2010](#CIT0028)), and the other was an open trial with only one arm (van den Berg & van der Gaag, [2012](#CIT0057)).

### 3.2.2.. Sample {#S0003-S2002-S3002}

A total sample of 236 adult participants were included in this review, with 106 of those participants treated with EMDR and 130 participating within the control or comparator groups. Sample sizes for the trials ranged from 27 to 155. Participants had a range of psychotic disorders across all of the studies including: schizophrenia; schizoaffective disorder; delusional disorders including olfactory reference syndrome (ORS), mood disorders including bipolar disorder with psychotic features, and psychotic disorders otherwise unspecified.

### 3.2.3.. EMDR {#S0003-S2002-S3003}

Five studies reported using Shapiro's ([2001](#CIT0048)) standard eight-phase EMDR protocol for the treatment of psychotic symptoms. The amount of EMDR sessions varied from one session (McGoldrick et al., [2008](#CIT0034) (cases 1 and 4) to 10 sessions (Kratzer et al., [2017](#CIT0031)). Only two studies reported treatment fidelity checks to ensure EMDR was conducted and administered as intended (de Bont et al., [2016](#CIT0008); Kim et al., [2010](#CIT0028)). Details of the fidelity checks can be seen in the supplementary material (Table S2).

The focus of EMDR differed amongst the studies. In three of the studies EMDR was used to treat Symptoms of PTSD in participants with a psychotic disorder by targeting and reprocessing traumatic life experiences that appeared to have caused the current PTSD (de Bont et al., [2016](#CIT0008); Laugharne et al., [2014](#CIT0032); van den Berg & van der Gaag, [2012](#CIT0057)). Kratzer et al.'s ([2017](#CIT0031)) study also evaluated EMDR for the treatment PTSD in a person with a psychotic disorder, however, they also used EMDR to specifically reduce psychotic symptoms by targeting and processing hallucinations associated with the participants dysfunctional beliefs about the self and the world. In one study EMDR was used to treat ORS by targeting the life experiences that triggered the disorder (McGoldrick et al., [2008](#CIT0034)). In another study EMDR was used to treat the acute phase of schizophrenia and the targets of EMDR were arbitrary and less specific than the other studies (Kim et al., [2010](#CIT0028)).

### 3.2.4.. Additional treatment {#S0003-S2002-S3004}

In all of the studies EMDR was provided alongside TAU. For the studies with participants based in the community settings this mainly consisted of psychotropic medications (de Bont et al., [2016](#CIT0008); Laugharne et al., [2014](#CIT0032); McGoldrick et al., [2008](#CIT0034); van den Berg & van der Gaag, [2012](#CIT0057)). For the studies with participants based in inpatient settings TAU consisted of psychotropic medication, group therapies such as art and exercise therapy, mindfulness and individual psychotherapy (Kratzer et al., [2017](#CIT0031); Kim et al., [2010](#CIT0028)).

### 3.2.5.. Outcome measures {#S0003-S2002-S3005}

Four studies reported outcomes from structured clinical interviews using Positive and Negative Syndrome Scale (PANSS; Kay, Opler, & Fiszbein, [1986](#CIT0026)) and/or the Psychotic Symptom Rating Scale (PSYRATS; Haddock, McCarron, Tarrier, & Faragher, [1999](#CIT0016)). Two studies used the Greens Paranoid Thoughts Scale (GPTS; Green et al., [2008](#CIT0015)), which is a self-report measure used to assess the severity of a person's paranoid thoughts.

3.3.. Results from clinical trials {#S0003-S2003}
----------------------------------

All three trials found an association between EMDR and a decrease in psychotic symptoms in different study populations and with different EMDR therapy objectives. Kim et al. ([2010](#CIT0028)) found all treatment groups improved significantly over time on all measures for people in an acute phase of schizophrenia, however, EMDR was not shown to be superior to PMR or TAU at 3- month follow-up. In respect to psychotic symptoms, two trials found opposing results for paranoid thinking according to GPTS scores and auditory hallucinations according to AHRS scores. de Bont et al. ([2016](#CIT0008)) found significant reductions in paranoid thinking, but auditory hallucinations remained unchanged across all groups, when treating PTSD in people with chronic psychotic disorders. Whereas, van den Berg and van der Gaag ([2012](#CIT0057)) found small statistically significant improvements in delusions and auditory hallucinations, but did not produce a significant effect on paranoid ideation, when treating people with psychosis and a comorbid PTSD.

de Bont et al. ([2016](#CIT0008)) were able to demonstrate that EMDR was superior to the waitlist control according to GPTS scores at post-treatment and 6-month follow-up. However, both studies with active comparison groups did not find a significant difference between the treatment groups (de Bont et al., [2016](#CIT0008); Kim et al., [2010](#CIT0028)). Participants in the EMDR and PE groups in de Bont et al.'s ([2016](#CIT0008)) study were significantly associated with more remissions from psychotic disorders than the waitlist condition according to SCI-SR-PANSS scores, however, this was not maintained at 6 or 12-month follow-up for the EMDR group. Despite no significant difference between groups for readmission rates in Kim et al.'s ([2010](#CIT0028)) study, only 18% of participants in the EMDR group had been readmitted to hospital at 2-year follow-up, compared with 42% in the PMR group and 33% in the TAU group.

The average dropout rate for EMDR across all three trials was 17%, and there was no statistical difference between groups for attrition in the two studies using comparison groups (de Bont et al., [2016](#CIT0008); Kim et al., [2010](#CIT0028)). Participants in Kim et al.'s ([2010](#CIT0028)) study did not show any exacerbations of any symptoms due to treatment and no one dropped out due to a worsening of their condition. In van den Berg and van der Gaag's ([2012](#CIT0057)) study, there were three incidences where participants reported brief exacerbation of their symptoms due to the EMDR treatment.

3.4.. Results from case series and case report {#S0003-S2004}
----------------------------------------------

All cases treated with EMDR in McGoldrick et al.'s ([2008](#CIT0034)) case series reached complete resolution of symptoms of ORS which was maintained at follow-up as long as 10 years (case 1). Kratzer et al.'s ([2017](#CIT0031)) case report found that the use of EMDR in an inpatient setting for people with psychosis and comorbid PTSD produced a clinically significant effect on PANSS- 22 scores, and symptom levels continued to decrease at 6-month follow-up. Across the case series and case report EMDR was associated with other health and well-being benefits including a reduction in psychotropic medication, improved social and general functioning, and a reduction in the use of mental health services.

Initial increases in positive psychotic symptoms were observed in one study (Kratzer et al., [2017](#CIT0031)). In Laugharne et al.'s ([2014](#CIT0032)) study one person relapsed once during a 5-year follow-up (case 2) and one person relapsed once during a 3-year follow-up after temporarily stopping antipsychotic medication (case 3).

4.. Discussion {#S0004}
==============

The use of EMDR was associated with reductions in delusional and negative symptoms of psychosis (de Bont et al., [2016](#CIT0008); Kim et al., [2010](#CIT0028); Kratzer et al., [2017](#CIT0031); Laugharne et al., [2014](#CIT0032); McGoldrick et al., [2008](#CIT0034); van den Berg & van der Gaag, [2012](#CIT0057)), and mixed findings were associated with auditory hallucinations and paranoid thinking (de Bont et al., [2016](#CIT0008); van den Berg & van der Gaag, [2012](#CIT0057)). EMDR was associated with more remissions from psychotic disorders than a waitlist condition (de Bont et al., [2016](#CIT0008)), fewer readmissions to hospital (Kim et al., [2010](#CIT0028)), and a reduction in the use of mental health services at follow-up as long as 10 years (McGoldrick et al., [2008](#CIT0034); Laugharne et al., [2014](#CIT0032)). This review aimed to evaluate EMDR's potential as a treatment for psychosis. Theoretically, EMDR should be suitable for any mental distress with a traumatic antecedent, which does not need to be of sufficient severity to classify as PTSD (Shapiro, [1995](#CIT0047)). There is increasing evidence to suggest that psychosis often occurs in people with a significant history of traumas. Although there is still limited research into the use of EMDR for people with psychosis, early indications suggest that it has potential to be a safe and beneficial intervention for this population (Swan et al., [2017](#CIT0051); Sin & Spain, [2017](#CIT0050); Valiente-Gomez et al., [2017](#CIT0053)).

EMDR appears to be a safe intervention for a range of mental health conditions (Carletto et al., [2017](#CIT0006); Doering, Ohlmeter, de Jongh, Hofmann, & Bisping, [2013](#CIT0012); Hase, Schallmayer, & Sack, [2008](#CIT0019)), and maybe the most poignant finding of this review is that EMDR can also be successfully and safely administered to people with a psychotic disorder with or without a comorbid PTSD. Studies included in this review negate longstanding concerns that treating trauma in people with psychosis will inevitably lead to exacerbations in psychotic symptoms and adverse events (Becker, Zayfert, & Anderson, [2004](#CIT0003); Gairns, Alvarez-Jimenez, Hulbert, McGorry, & Bendall, [2015](#CIT0014)). EMDR did not lead to any adverse events such as suicide attempts, aggression or hospital admissions in any of the included studies. Two of the studies in this review reported that there were no adverse events or exacerbations of symptoms during or after treatment (Kim et al., [2010](#CIT0028); Laugharne et al., [2014](#CIT0032)), and EMDR was associated with significantly less adverse events compared to the wait-list condition in de Bont et al.'s ([2016](#CIT0008)) study. The studies in this review complement the existing literature which suggests TFTs including EMDR are safe to use for people with psychosis, with some studies finding they appear to reduce the adversities experienced by this population compared to wait list conditions (de Bont, van Minnen, & de Jongh, [2013b](#CIT0010); van den Berg et al., [2016](#CIT0055)).

Across the studies EMDR was associated with a statistically and clinically significant decrease in some positive and negative psychotic symptoms, although there were contrasting results for paranoid thinking measured by the GPTS and auditory hallucinations measured by the AHRS (de Bont et al., [2016](#CIT0008); van den Berg & van der Gaag, [2012](#CIT0057)). These differences could be explained by small sample sizes and subsequent lack of power leading to skewed results (Teare et al., [2014](#CIT0052)). Another plausible contributing factor for the inconsistency in paranoid symptoms could be the use of self-report measures such as the GPTS. These measures are inevitably prone to response bias in which participants can consciously or unconsciously affect outcomes leading to distorted results (Abernethy, [2015](#CIT0001)).

Sample size and a lack of power is problematic throughout the included trials preventing smaller outcome differences from being detected, potentially affecting the outcomes for EMDR (Sabo & Boone, [2013](#CIT0043)). Kim et al.'s ([2010](#CIT0028)) study demonstrates that EMDR was associated with considerably fewer readmissions to hospital (18%) at 2-year follow-up, in comparison to 42% for the attention-placebo group and 33% for the TAU group. Despite these percentages being largely in favour of EMDR, the results were not regarded as statistically significant. Both trials using active comparators were unable to demonstrate that EMDR was superior despite Kim et al.'s ([2010](#CIT0028)) study showing a larger effect size for negative symptoms than the PMR and TAU groups.

Results of the studies with longer follow-up periods (McGoldrick et al., [2008](#CIT0034); Kim et al., [2010](#CIT0028)) provide preliminary evidence that EMDR could potentially provide sustained recovery preventing relapse and readmissions for people with psychosis. The case series in this review with longer follow-up provide valuable insight into the wider impacts on EMDR on a person's life beyond symptom change that contribute to recovery. Both case series note a marked improvement in functioning in most cases with some people returning to full-time employment (McGoldrick et al., [2008](#CIT0034); Laugharne et al., [2014](#CIT0032)). They also report a reduction in the use of psychiatric medication and mental health service use. Reducing the use of psychiatric medication could significantly improve the health, functioning, quality of life and mortality rates of people with psychosis, whereas reduction in the use of services could generate considerable cost savings for the NHS (de Lusignan, Chan, Parry, Dent-Brown, & Kendrick, [2012](#CIT0011)). These findings should prompt more rigorous confirmatory trials to include outcome measures beyond symptom change with adequate follow-up periods, as decreased service use, economic impact, and improved functioning are also indicators of an intervention's success.

The acceptability of an intervention is a necessary criterion for its overall effectiveness, and is often determined by dropout rates (Sekhon, Cartwright, & Francis, [2017](#CIT0044)). The average dropout rate across the three trials was 17% (de Bont et al., [2016](#CIT0008); Kim et al., [2010](#CIT0028); van den Berg & van der Gaag, [2012](#CIT0057)). This mirrors a previous meta-analysis that found an average dropout rate of 18% for trauma-focused interventions for the treatment of PTSD (Imel, Laska, Jakupcak, & Simpson, [2013](#CIT0023)). Interpreting the number of dropouts as an indicator of acceptability may be misleading, as someone may think the intervention is entirely acceptable and terminated treatment prematurely simply because their symptoms resolved; or for unrelated reasons such as getting a new job making it difficult to get to appointments (Sekhon et al., [2017](#CIT0044)). Future research using large, adequately powered, and rigorously performed RCTs with substantial follow-up, which incorporate qualitative methods to capture service user experiences would contribute to this conversation.

4.1.. Strengths and limitations of the review {#S0004-S2001}
---------------------------------------------

This is the first systematic review of the evidence of EMDR as a treatment for psychosis. It is important to note that the populations and focus of EMDR varied amongst the studies. Four of the studies were focussed on evaluating the safety of using EMDR when treating PTSD in people with a psychotic disorder (de Bont et al., [2016](#CIT0008); Kratzer et al., [2017](#CIT0031); Laugharne et al., [2014](#CIT0032); van den Berg & van der Gaag, [2012](#CIT0057)). For these studies, it is difficult to tell whether EMDR was directly responsible for the reduction in psychotic symptoms, or whether it was the reduction in PTSD symptoms that caused subsequent reductions in psychotic symptoms. The two studies evaluating EMDR for the treatment of people with psychosis without a comorbid PTSD were able provide preliminary findings that EMDR could be a useful treatment for psychosis, but these studies are of lower quality (McGoldrick et al., [2008](#CIT0034); Kim et al., [2010](#CIT0028)).

Similar to Swan et al.'s ([2017](#CIT0051)) systematic review of psychological interventions for post- traumatic stress symptoms in psychosis, a strength of this review is the broad search strategy facilitating the inclusion of a variety of study designs. A broad search strategy ensured that no potentially relevant studies were missed, and an inclusive review was produced incorporating all relevant findings within the current literature irrespective of study design. However, although its main strength, the broad inclusion criteria yielded studies which overall are considered poor quality for evaluating the effectiveness of an intervention. Three studies were descriptive studies without a control group and two were pilot studies. Therefore, this review was unable to produce strong inferences regarding the effectiveness of EMDR for people with psychosis.

4.2.. Conclusion {#S0004-S2002}
----------------

This systematic review adds to the growing body of evidence that supports the use of trauma- focused interventions for individuals experiencing psychosis (Swan et al., [2017](#CIT0051); Sin & Spain, [2017](#CIT0050); Valiente-Gomez et al., [2017](#CIT0053)). Despite exciting results highlighting the potential benefits of EMDR for the treatment of psychosis, the lack of definitive, high-powered RCTs found, limits any conclusions on the overall effectiveness. However, this review found that EMDR did not lead to any adverse events, and appears a safe and feasible intervention for people both in a stable and acute phase of psychosis, with or without a comorbid PTSD. This review also found comparable dropout rates to existing research evaluating trauma-focused interventions for individuals with PTSD, indicating this population is no more likely to terminate EMDR prematurely than others. However, an adequate evaluation of the acceptability of EMDR for people with psychosis was not possible, as the studies included did not adequately address this issue.

4.3.. Implications for practice {#S0004-S2003}
-------------------------------

This review provides evidence that EMDR can be safely and successfully applied to this people with psychosis, with evidence of some beneficial effects. Therefore, in practice EMDR could be considered an appropriate treatment for people with psychosis who have been exposed to trauma, based on their individual assessments and clinical needs. It is important to note that some of the studies in this review observed initial increases in psychotic symptoms (Kratzer et al., [2017](#CIT0031); van den Berg & van der Gaag, [2012](#CIT0057)). Although some studies have found that EMDR can be used effectively with this population without the use of additional stabilizing interventions (Hardy & van den Berg, [2016](#CIT0018); van den Berg et al., [2015](#CIT0056), [2016](#CIT0055)), initial increases in symptoms highlight the need to view EMDR as a protocol rather than just bilateral stimulation, as there must be sufficient preparation and work on emotional stability before moving on to bilateral stimulation. This also indicates the need for a multidisciplinary team to support people whilst undergoing EMDR in community settings. Due to the initial increase in psychotic symptoms observed in Kratzer et al.'s ([2017](#CIT0031)) study, they suggest administering EMDR in an inpatient setting may be beneficial, as there would be more support available if the intervention increases distress that cannot be adequately managed in the community.

4.4.. Implications for future research {#S0004-S2004}
--------------------------------------

The studies in this review have opened up new areas for learning and generated hypotheses that more rigorous trials can evaluate. Larger confirmatory RCTs directly comparing EMDR with 'gold standard' treatments, such as CBT or antipsychotic medication, are required to form more robust conclusions regarding the efficacy of EMDR for the treatment of psychosis. Future trials should ensure they are methodologically sound and sufficiently powered to detect smaller outcome differences, and include outcome measures at follow-up targeting any increase or decrease in mental health services and psychotropic medications. All future research should measure acceptability and rigorously record any adverse outcomes (Duggan, Parry, McMurran, Davidson, & Dennis, [2014](#CIT0013)). Future research should also include stringent fidelity checks preferably using the EMDR Fidelity Rating Scale (EFRS) (Korn, Maxfield, Smyth, & Stickgold, [2017](#CIT0030)). Adherence to treatment protocols confirmed by fidelity rating scales is considered essential for any rigorous RCT (Korn et al., [2017](#CIT0030)), and fidelity to the treatment model is crucial to success when translating evidence- based interventions into practice (Breitenstein et al., [2010](#CIT0005)).
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###### Supplemental Material

[^1]: ITT = Intention-to-treat. LOCF = Last observation carried forward. DRS = Delusion rating scale. GPTS = Green paranoid thought scale.

[^2]: RCT = Randomized Controlled Trial. PTSD = Post-traumatic Stress Disorder. TFT = Trauma-Focused Therapy. ORS = Olfactory Reference Syndrome. n = Sample size. EMDR = Eye Movement Desensitization and Reprocessing. PMR = Progressive Muscle Relaxation. TAU = Treatment as usual. PANSS = Positive and Negative Syndrome Scale. PTSD = Post-traumatic stress disorder. GPTS = Greens Paranoid Thoughts Scale. PSYRATS = Psychotic Symptom Rating Scale. PSYRATS is a measure consisting of two brief structured interviews: the auditory hallucination rating scale (AHRS) and the delusion rating scale (DRS). PE = Prolonged exposure SCI-SR-PANSS = The structured clinical interview for symptoms of remission for the positive and negative syndrome scale. DSM = Diagnostic and Statistical Manual of Mental Health Disorders. CBT = Cognitive behavioural therapy. CI = Confidence intervals. WL = Waitlist. \* = significant at p \< 0.05

    NB -- Remission status: if no SCI-PANSS symptoms of psychosis interfere with functioning an individual is rated in remission.
